Slingshot members are tracking this event:

AbbVie's (ABBV) RINVOQ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis, Receives FDA Approval

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details - RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis

- Durable remission rates with RINVOQ (as assessed by DAS28-CRP<2.6) were observed at week 26

- RINVOQ significantly inhibited radiographic progression even without methotrexate

- Approval supported by efficacy and safety data from one of the largest registrational Phase 3 programs in rheumatoid arthritis with approximately 4,400 patients evaluated across five studies

- Discovered and developed by AbbVie, RINVOQ marks the second U.S. FDA approval of a targeted immunomodulator (TIM) therapy for AbbVie this year
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 16, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Rinvoq, Upadacitinib, Jak Inhibitor, Rheumatoid Arthritis